Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Scientists Develop More Precise Genetic Off Switches

October 29, 2010 8:16 am | News | Comments

Researchers have found a way to "cage" genetic off switches in such a way that they can be activated when exposed to UV light. Their technology gives scientists a more precise way to control and study gene function in localized areas of developing organisms.


Pfizer Recalling Lipitor

October 29, 2010 8:13 am | News | Comments

Pfizer says it is recalling 38,000 bottles of the cholesterol drug Lipitor, its best-selling product, due to reports of a musty or moldy odor.


Cancer’s Hiding Spots Revealed

October 29, 2010 8:10 am | News | Comments

After receiving chemotherapy, many cancer patients go into a remission that can last months or years. But in some of those cases, tumors eventually grow back, and when they do, they are frequently resistant to the drugs that initially worked.


Positive Results in Phase 2 Locteron Trial

October 29, 2010 8:03 am | News | Comments

Biolex Therapeutics, Inc. announced positive efficacy, safety and tolerability results from its 72-week SELECT-2 Phase 2b dose-finding Phase 2b trial of Locteron, the company’s lead product candidate for the treatment of hepatitis C.


FDA Refuses Approval for Qnexa

October 29, 2010 7:58 am | by Matthew Perrone | News | Comments

Federal health regulators have decided not to approve an experimental diet pill called Qnexa, which had been touted by many experts as the most promising weight-loss drug in more than a decade.


Malaria Extermination Efforts Futile Without Vaccine

October 29, 2010 7:56 am | by Maria Cheng | News | Comments

Eliminating malaria, the mosquito-borne scourge that kills more than 860,000 people a year, would be a dream come true for millions - but medical experts say right now that goal remains completely unrealistic.


Merck Posts 90% Drop in Profits

October 29, 2010 7:53 am | by Linda A. Johnson | News | Comments

Merck & Co. posted a 90 percent drop in third-quarter profit, due to large charges for its $41.1 billion acquisition last year of Schering-Plough Corp. and a legal reserve set up because of a federal investigation.


Solutions Address Global Drug Counterfeiting Epidemic

October 29, 2010 6:06 am | News | Comments

A new report has identified the need for more consumer education, improved regulatory standards, and solutions that businesses can use to address this growing public health threat associated with counterfeit medicine.


Global Supply Chain Increases Risks, Threats

October 29, 2010 5:56 am | News | Comments

Global pharmaceutical outsourcing has become increasingly prevalent, but is creating a complex and risky supply chain environment that has pharmaceutical and life sciences executives on high alert.


DNA Analysis

October 28, 2010 5:21 am | Drug Discovery & Development | Product Releases | Comments

ZyGEM Corp. Ltd., announced several developments supporting the advancement of its integrated microfluidics platform designed to dramatically decrease the time, complexity and cost of conducting DNA testing.


Lead Optimization Tool

October 28, 2010 5:19 am | Product Releases | Comments

InhibOx Ltd announces LOx 2.0 - a flexible system to identify and optimize drug lead candidates through preserving and linking critical features with new scaffolds.


Stem Cells + Protein = Cancer

October 28, 2010 5:16 am | News | Comments

Researchers at North Carolina State University have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. Their work may lead to new treatments for a variety of cancers.


Concerns Raised About 'Healthy' Antioxidants

October 28, 2010 5:14 am | News | Comments

Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants — including those with the apparent ability to prevent cancer — may actually aggravate or even cause cancer in some individuals.


GlobeImmune Expands GI-5005 Trial

October 28, 2010 5:11 am | News | Comments

GlobeImmune Inc. announced the expansion of its Phase 2b clinical trial of GI-5005, an investigational Tarmogen product for the treatment of hepatitis C virus infection. The company previously reported a 60% improvement in sustained virologic response.


Ligocyte VLP Candidate Performs Well in Phase 1/2

October 28, 2010 5:08 am | News | Comments

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing vaccine products, announced positive results from a Phase 1/2 challenge study of its norovirus virus-like particle (VLP) vaccine candidate.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.